한글목차

SUNOSI는 도파민 노르에피네프린 재흡수 억제제(DNRI)로 기면증 또는 OSA로 인한 EDS를 가진 성인의 각성 개선에 대한 적응증으로 2014년 Jazz Pharmaceuticals는 Aerial Biopharma로부터 SUNOSI의 개발 및 상업화 라이선스를 획득했습니다.의 개발 및 상업화 라이선스를 취득했으며, 재즈 파마슈티컬스는 아시아 일부 지역을 제외한 전 세계에 대한 개발, 제조 및 상업화 권리를 보유하고 있습니다. 이 화합물의 발견자인 SK바이오팜은 한국, 중국, 일본을 포함한 12개 아시아 시장에 대한 권리를 보유하고 있습니다.

앞으로 몇 년동안 폐쇄성 수면무호흡증(OSA) 시장 시나리오는 전 세계적으로 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 회사는 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, SUNOSI의 우위에 영향을 미칠 수 있는 기회를 모색하고 있습니다. 다른 OSA 치료제들도 SUNOSI와 치열한 시장 경쟁을 벌일 것으로 예상되며, 가까운 시일 내에 후발 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

이 보고서는 주요 6개국에서 폐쇄성 수면무호흡증(OSA) 치료제인 SUNOSI 시장에 대해 조사했으며, 시장 개요, 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등의 정보를 전해드립니다.

목차

제1장 보고서 서론

제2장 OSA 치료제 SUNOSI 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신흥 치료법)

제5장 SUNOSI 시장 평가

• OSA 치료제 SUNOSI 시장 전망
• 주요 6개국 분석
  • 주요 6개국의 OSA 치료제 SUNOSI 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

"SUNOSI Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about SUNOSI for Obstructive sleep apnea (OSA) in the six major markets. A detailed picture of the SUNOSI for OSA in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 -2032 is provided in this report along with a detailed description of the SUNOSI for OSA. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SUNOSI market forecast analysis for OSA in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.

Drug Summary:

SUNOSI is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and is indicated to improve wakefulness in adults living with EDS due to narcolepsy or OSA. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize SUNOSI from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to SUNOSI, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China, and Japan.

Dosage

• The drug is administered once daily upon awakening and is recommended to avoid administration within 9 h of planned bedtime because of the potential to interfere with sleep
• Starting dose for patients with narcolepsy: 75 mg once daily
• Starting dose for patients with OSA: 37.5 mg once daily
• The dose may be increased at intervals of at least 3 days
• The maximum dose is 150 mg once daily

Mechanism of action

The mechanism of action of solriamfetol to improve wakefulness in patients with EDS associated with narcolepsy or OSA is unclear. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine reuptake inhibitor (DNRI).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the SUNOSI description, mechanism of action, dosage and administration, research and development activities in Obstructive sleep apnea (OSA).
• Elaborated details on SUNOSI regulatory milestones and other development activities have been provided in this report.
• The report also highlights the SUNOSI research and development activities in OSA across the United States and Europe.
• The report also covers the patents information with expiry timeline around SUNOSI.
• The report contains forecasted sales of SUNOSI for OSA till 2032.
• Comprehensive coverage of the late-stage emerging therapies for OSA.
• The report also features the SWOT analysis with analyst views for SUNOSI in OSA.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SUNOSI Analytical Perspective by DelveInsight

• In-depth SUNOSI Market Assessment

This report provides a detailed market assessment of SUNOSI for Obstructive sleep apnea (OSA) in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2024 to 2032.

• SUNOSI Clinical Assessment

The report provides the clinical trials information of SUNOSI for OSA covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Obstructive sleep apnea (OSA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SUNOSI dominance.
• Other emerging products for OSA are expected to give tough market competition to SUNOSI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SUNOSI in OSA.
• Our in-depth analysis of the forecasted sales data of SUNOSI from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SUNOSI in OSA.

Key Questions:

• What is the product type, route of administration and mechanism of action of SUNOSI?
• What is the clinical trial status of the study related to SUNOSI in Obstructive sleep apnea (OSA) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SUNOSI development?
• What are the key designations that have been granted to SUNOSI for OSA?
• What is the forecasted market scenario of SUNOSI for OSA?
• What are the forecasted sales of SUNOSI in the six major countries, including the United States, Europe (Germany, France, Italy, and Spain) and the United Kingdom?
• What are the other emerging products available and how are these giving competition to SUNOSI for OSA?
• Which are the late-stage emerging therapies under development for the treatment of OSA?

Table of Contents

1. Report Introduction

2. SUNOSI Overview in OSA

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SUNOSI Market Assessment

• 5.1. Market Outlook of SUNOSI in OSA
• 5.2. 6MM Analysis
  • 5.2.1. Market Size of SUNOSI in the 6MM for OSA
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of SUNOSI in the United States for OSA
  • 5.3.2. Market Size of SUNOSI in Germany for OSA
  • 5.3.3. Market Size of SUNOSI in France for OSA
  • 5.3.4. Market Size of SUNOSI in Italy for OSA
  • 5.3.5. Market Size of SUNOSI in Spain for OSA
  • 5.3.6. Market Size of SUNOSI in the United Kingdom for OSA

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options